ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0382

Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation

Ilaria Maccora1, Mariia Pavlenko2, Jackeline Rodriguez-Smith3, Amy Cassedy4, Mekibib Altaye5, hermine brunner6, Alexandra Duell5, Alexei Grom5, Theresa Hennard7, Virginia Miraldi Utz5, Najima Mwase5, Megan Quinlan-Waters5, grant schulert5, Alyssa Sproles8, Jessica Shantha9, Sunil K Srivastava10, Sherry Thornton8, Steven Yeh11 and sheila Angeles-Han12, 1?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 2Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, 4Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 7Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 8Cincinnati Children's Hospital, Cincinnati, 9UCSF/Proctor Foundation, San Francisco, IL, 10Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, 11Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, 12Cincinnati Children's Hospital, Cincinnati, OH

Meeting: ACR Convergence 2024

Keywords: Biomarkers, Eye Disorders, Inflammation, Juvenile idiopathic arthritis, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination wherein the extent of inflammation can vary between eyes of an affected child. In a study of adults with uveitis, SERPINA3, an acute phase protein, was increased in the tear samples of the unaffected eyes of patients with unilateral anterior uveitis compared to healthy controls. Our aim is to determine if tear-based biomarker levels differ in the affected and controlateral eye based on the presence/degree of eye inflammation.

Methods: In our cross-sectional study, we collected tear fluid by Schirmer strips from JIA-U children who were older than 5 years of age. JIA-U activity was graded according to the Standardization of Uveitis Nomenclature (SUN) criteria. Inactive JIA-U was defined as anterior chamber (AC) cells=0, and active was AC >0.5+. Only children with samples from both eyes were included. Cytokines, chemokines and S100 proteins were measured by Luminex and ELISA assays. Children were grouped by history of bilateral or unilateral uveitis. We compared levels of these inflammatory mediators in both eyes by laterality and grade of inflammation at time of clinical examination. History of bilateral uveitis: a) both active eyes, b) one active eye to one inactive eye, and c) two inactive eyes. History of unilateral uveitis: a) one active eye or b) one inactive eye to the unaffected contralateral eye. Each eye biomarker score was logged to the 10th in order to create a normal distribution for that biomarker. Paired T-Tests were used to determine if there were statistically significant differences in the mean percent biomarker level of each eye per patient for each biomarker. 

Results: Demographic and treatment characteristics for the 41 patients are found in table 1. Thirty (73%) patients had bilateral JIA-U while 11 (27%) had unilateral JIA-U. The 41 patients contributed 68 paired samples (both eyes), 17 pairs had bilateral JIA-U active eyes (10 with both eyes active and 7 with one eye active), 31 pairs bilateral inactive (both eyes inactive), 8 pairs unilateral active, and 12unilateral inactive. In children with bilateral active JIA-U, we did not observe significant difference, while in children with unilateral active JIAU we observed a mean percent difference in biomarker levels between right and left eyes on IP-10 and S100A12 (p0.04 and 0.034) (Table 2). When isolating bilateral pairs with both eyes active, we found mean percent differences in IL-18 and MCP-1 (p0.035 and p 0.025, Table 3).

Conclusion: In conclusion, our results show that IP-10, IL-18, S100A12 and MCP-1 levels differed between eyes of patients with JIA-U based on laterality of involvement and presence and severity of inflammation. No differences were found between the affected and contralateral eye in those with unilateral JIA-U. JIA-U is usually bilateral, but inflammation can vary in the eyes of an individual child. Given that the unaffected eyes in patients with unilateral uveitis and the inactive eye in patients with bilateral uveitis were similar to the contralateral eyes, this suggests possible crossing of inflammatory mediators across the ocular retinal barrier.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: I. Maccora: None; M. Pavlenko: None; J. Rodriguez-Smith: None; A. Cassedy: None; M. Altaye: None; h. brunner: AbbVie/Abbott, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb, 2, 12, Contributions, Celgene, 2, Eli Lilly, 2, 12, Contributions, EMD Serono, 2, F. Hoffmann-La Roche, 2, 12, Contributions, GlaxoSmithKlein(GSK), 2, 6, 12, Contributions, Janssen, 2, 12, Contributions, Merck/MSD, 2, Novartis, 2, 6, 12, Contributions, Pfizer, 2, 12, Contributions, Roche, 6, R-Pharm, 2, Sanofi, 2, UCB, 2; A. Duell: None; A. Grom: None; T. Hennard: None; V. Miraldi Utz: None; N. Mwase: None; M. Quinlan-Waters: None; g. schulert: Boehringer-Ingelheim, 2, IpiNovyx, 5, SOBI, 2; A. Sproles: None; J. Shantha: None; S. Srivastava: None; S. Thornton: None; S. Yeh: None; s. Angeles-Han: None.

To cite this abstract in AMA style:

Maccora I, Pavlenko M, Rodriguez-Smith J, Cassedy A, Altaye M, brunner h, Duell A, Grom A, Hennard T, Miraldi Utz V, Mwase N, Quinlan-Waters M, schulert g, Sproles A, Shantha J, Srivastava S, Thornton S, Yeh S, Angeles-Han s. Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparative-analysis-of-tear-based-s100-proteins-cytokines-and-chemokines-levels-in-juvenile-idiopathic-arthritis-associated-uveitis-insights-into-eye-laterality-and-severity-of-ocular-inflammation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-analysis-of-tear-based-s100-proteins-cytokines-and-chemokines-levels-in-juvenile-idiopathic-arthritis-associated-uveitis-insights-into-eye-laterality-and-severity-of-ocular-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology